Abstract
We have shown that Cyr61, an angiogenic regulator, is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies. We have further demonstrated that Cyr61 promotes acquisition of estrogen-independence and anti-estrogen resistance in vivo in breast cancer cells. Moreover, we have demonstrated that Cyr61 induces tumor formation and tumor vascularization in vivo, events mediated through the activation of the MAPK and the Akt signaling pathways. Here we investigate how Cyr61 expression is regulated in both estrogen receptor (ER)-positive and ER-negative breast cancer cells. We demonstrate that Cyr61 mRNA and protein expression is inducible by estrogen and anti-estrogens in ER-positive breast cancer cells. We show that a labile protein as well as a negative regulator might be involved in Cyr61 expression in estrogen-dependent breast cancer cells. Other important regulators of Cyr61 expression in breast cancer cells that we found are the phorbol ester TPA, vitamin D, and retinoic acid. TPA causes positive regulation of Cyr61 expression in ER-positive MCF-7 cells. Vitamin D induces a transient stimulatory effect on Cyr61 gene expression. Lastly, retinoic acid has a negative effect on Cyr61 expression and downregulates its expression in MCF-7 cells. Interestingly, most of these effects are not seen in aggressive breast cancer cells that do not express ER and express high levels of Cyr61, such as the MDA-MB-231 cells. Our results are in agreement with our knowledge that Cyr61 promotes tumor growth, and that tumor-promoting agents have a positive impact on cells that express low levels of Cyr61, such as the ER-positive breast cancer cells; however, these agents have no significant effect on cells that express high levels of Cyr61. Our findings suggest an association between increased Cyr61 expression and an aggressive phenotype of breast cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agadir A, Chen GQ, Bost F, Li Y, Mercola D, Zhang X . 1999 J. Biol. Chem. 274: 29779–29785
Albrecht C, von der Kammer H, Mayhaus M, Klaudiny J, Schweizer M, Nitsch RM . 2000 J. Biol. Chem. 275: 28929–28936
Babic AM, Kireeva ML, Kolesnikova TV, Lau LF . 1998 Proc. Natl. Acad. Sci. USA 95: 6355–6360
Babic AM, Chen CC, Lau LF . 1999 Mol. Cell. Biol. 19: 2958–2966
Bowden ET, Barth M, Thomas D, Glazer RI, Mueller SC . 1999 Oncogene 18: 4440–4449
Bunner A, Chinn J, Neubauer M, Purchio AF . 1991 DNA Cell Biol. 10: 293–300
Chen N, Chen CC, Lau LF . 2000 J. Biol. Chem. 275: 24953–24961
Chung KC, Ahn YS . 1998 Neurosci. Lett. 255: 155–158
Escaleira MT, Brentani MM . 1999 Breast Cancer Res. Treat. 54: 123–133
Flicker SH, Schneider SM, Offterdinger M, Dittrich E, Fazeny B, Valenta R, Huber H, Dittrich C, Crung TW . 1997 Cancer Lett. 115: 63–72
Folgueira MA, Federico MH, Roela RA, Maistro S, Katayama ML, Brentani MM . 2000 Braz. J. Med. Biol. Res. 33: 559–568
Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR . 1996 J. Invest Dermatol. 107: 404–411
Glass CK, Rose DS, Rosenfeld MG . 1997 Curr. Opin. Cell Biol. 9: 222–232
Grzeszkiewicz TM, Kirschling DJ, Chen N, Lau LF . 2001 J. Biol. Chem. 276: 21934–21950
Haussler MR, Jurutka PS, Hsieh JC, Thompson PD, Selznick SH, Haussler CA, Whitfield GK . 1995 Bone 17: 33S–38S
Inuzuka H, Nanbu-Wakao R, Masuho Y, Muramatsu M, Tojo H, Wakao H . 1999 Biochem. Biophys. Res. Commun. 265: 664–668
Jedsadayanmata A, Chen CC, Kireeva ML, Lau LF, Lam SC . 1999 J. Biol. Chem. 274: 24321–24327
Kireeva ML, Mo F-E, Yang GP, Lau LF . 1996 Mol. Cell. Biol. 16: 1326–1334
Kireeva ML, Latinkic BV, Kolesnikova TV, Chen CC, Yang GP, Abler AS, Lau LF . 1997 Exp. Cell Res. 233: 63–77
Kireeva ML, Lam SC, Lau LF . 1998 J. Biol. Chem. 273: 3090–3096
Kolesnikova TV, Lau LF . 1998 Oncogene 16: 747–754
Lau LF, Lam SC . 1999 Exp. Cell Res. 246: 44–57
Lau LF, Nathans D . 1987 Proc. Natl. Acad. Sci. USA 84: 182–186
MacGregor JI, Jordan VC . 1988 Pharmacol. Rev. 50: 151–196
Nathans D, Lau LF, Christy B, Hartzell S, Nakabeppu Y, Ryder K . 1988 Cold Spring Harbor Symp. Quant. Biol. 53: 893–900
Nolan E, Donepudi M, Van Weelden K, Flanagan L, Welsh J . 1998 Mol. Cell. Biochem. 188: 13–20
O'Brien TP, Lau LF . 1992 Cell Growth Differ. 3: 645–654
Pendurthi UR, Allen KE, Ezban M, Rao LV . 2000 J. Biol. Chem. 275: 14632–14641
Rivera-Gonzalez R, Petersen DN, Tkalcevic G, Thompson DD, Brown TA . 1998 J. Steroid Biochem. Mol. Biol. 64: 13–24
Ryseck RP, Macdonald-Bravo H, Mattéi MG, Bravo R . 1991 Cell Growth Differ. 2: 225–233
Sampath D, Winneker RC, Zhang Z . 2001 Endocrinology 142: 2540–2548
Scheutze N, Lechner A, Groll C, Siggelkow H, Heufner M, Keohrle J, Jakob F . 1998 Endocrinology 139: 1761–1770
Schneider SM, Offterdinger M, Huber H, Grunt TW . 1999 Breast Cancer Res Treat. 58: 171–181
Sheikh MS, Shao ZM, Li XS, Dawson M, Jetten AM, Wu S, Conley BA, Garcia M, Rochefort H, Fontana JA . 1994 J. Biol. Chem. 269: 21440–21447
Smith JB, Herschman HR . 1995 J. Biol. Chem. 270: 16756–16765
Srivastava RK, Srivastava SR, Cho-Chung YS, Longo DL . 1999 Clin. Cancer Res. 5: 1892–1904
Tang C, Grunt T, Cho C, Weibel C, Perez C, Lupu R . 1996 Cancer Res. 56: 3350–3358
Tsai M-S, Hornby AE, Lakins J, Lupu R . 2000 Cancer Res. 60: 5603–5607
Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, Said JW, Gornbein J, Koeffler HP . 2001 J. Biol. Chem. 276: 14187–14194
Yang PG, Lau FL . 1991 Cell Growth Differ. 2: 351–357
Wong M, Kireeva ML, Kolesnikova TV, Lau LF . 1997 Dev. Biol. 192: 492–508
Acknowledgements
The authors wish to thank Eddie Lo for technical assistance and Kevin Peet for editorial support. This work was supported by grants from the National Institutes of Health (DK49049), and from the Department of Energy (DE-AC03-76SF00098), and M-S Tsai was the recipient of a Breast Cancer Research Program Postdoctoral Traineeship from the Department of Defense.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsai, MS., Bogart, D., Li, P. et al. Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene 21, 964–973 (2002). https://doi.org/10.1038/sj.onc.1205131
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205131
Keywords
This article is cited by
-
Aberrant activation of CYR61 enhancers in colorectal cancer development
Journal of Experimental & Clinical Cancer Research (2019)
-
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology (2017)
-
Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer
Clinical and Translational Oncology (2017)
-
MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN
Tumor Biology (2014)
-
MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61
Tumor Biology (2014)